https://orcid.org/0000-0002-0348-3664
References
- Poudel A, Peel NM, Nissen LM, et al. Adverse outcomes in relation to polypharmacy in robust and frail older hospital patients. J Am Med Dir Assoc. 2016;17(8):767.e9-767.e13.
- Scottish Government Polypharmacy Model of Care Group. Polypharmacy guidance, realistic prescribing. Scottish Government; 2018.
- Bennett A, Gnjidic D, Gillett M, et al. Prevalence and impact of fall-risk-increasing drugs, polypharmacy, and drug-drug interactions in robust versus frail hospitalised falls patients: a prospective cohort study. Drugs Aging. 2014;31(3):225–232.
- Shmuel S, Lund JL, Alvarez C, et al. Polypharmacy and incident frailty in a longitudinal community-based cohort study. J Am Geriatr Soc. 2019;67(12):2482–2489.
- Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol. 2017;73(6):759–770.
- Herr M, Sirven N, Grondin H, et al. Frailty, polypharmacy, and potentially inappropriate medications in old people: findings in a representative sample of the French population. Eur J Clin Pharmacol. 2017;73(9):1165–1172.
- Midão L, Giardini A, Menditto E, et al. Polypharmacy prevalence among older adults based on the survey of health, ageing and retirement in Europe. Arch Gerontol Geriatr. 2018;78:213–220.
- Melzer D, Tavakoly B, Winder R, et al. Much more medicine for the oldest old: trends in UK electronic clinical records. Age Ageing. 2014;44(1):46–53.
- Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011;171(6):550–556. .
- Cerreta F, Ankri J, Bowen D, et al. Baseline frailty evaluation in drug development. J Frailty Aging. 2016;5(3):139–140.
- Rockwood K, Mitnitski A. How might deficit accumulation give rise to frailty? J Frailty Aging. 2012;1(1):8–12.
- Morley J, Vellas B, Abellan van Kan G, et al. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013;14(6):392–397.
- Cesari M, Pérez-Zepeda M, Marzetti E. Frailty and multimorbidity: different ways of thinking about geriatrics. J Am Med Dir Assoc. 2017;18(4):361–364.
- Cesari M, Vellas B, Gambassi G. The stress of aging. Exp Gerontol. 2013;48(4):451–456.
- Carbonin P, Pahor M, Bernabei R, et al. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc. 1991;39(11):1093–1099.
- Savage RD, Visentin JD, Bronskill SE, et al. Evaluation of a common prescribing cascade of calcium channel blockers and diuretics in older adults with hypertension. JAMA Intern Med. 2020;180(5):643–651.
- Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf. 2016;7(1):11–22.
- Integrated care for older people (ICOPE): guidance for person-centred assessment and pathways in primary care. World Health Organization; 2019.
- Mangin D, Bahat G, Golomb BA, et al. International group for reducing inappropriate medication use & polypharmacy (IGRIMUP): position statement and 10 recommendations for action. Drugs Aging. 2018;35(7):575–587.
- Fried TR, Street RL, Cohen AB. Chronic disease decision making and “what matters most„. J Am Geriatr Soc. 2020;68(3):474–477.
- Gutiérrez-Valencia M, Izquierdo M, Lacalle-Fabo E, et al. Relationship between frailty, polypharmacy, and underprescription in older adults living in nursing homes. Eur J Clin Pharmacol. 2018;74(7):961–970.
- Gutiérrez-Valencia M, Izquierdo M, Cesari M, et al. The relationship between frailty and polypharmacy in older people: A systematic review: frailty and polypharmacy: A systematic review. Br J Clin Pharmacol. 2018;84(7):1432–1444.
- Fried T, O’Leary J, Towle V, et al. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc. 2014;62(12):2261–2272.
- Marzetti E, Sanna T, Calvani R, et al. Brand new medicine for an older society. J Am Med Dir Assoc. 2016;17(6):558–559.